Facilitating direct T-cell mediated cytotoxicity, this specialized program utilizes bispecific antibodies to simultaneously target B7-H4 expressing tumors and CD3 on T-cells to overcome microenvironmental immune evasion.
Learn More →Next-IO™ APC related Therapeutics
Creative Biolabs delivers a comprehensive, end-to-end service ecosystem dedicated to the discovery and sophisticated development of APC-targeted molecules. Our proprietary platform integrates computational antigen prediction with expert chemical conjugation and rigorous functional validation across diverse cellular and animal models. By partnering with our specialists, clients secure high-affinity lead candidates supported by exhaustive mechanism-of-action data. We provide a highly streamlined pathway for identifying viable therapeutic tools, focusing specifically on optimizing immune priming through the precise molecular modulation of the critical APC-T cell synapse.
Introduction What We Can Offer How We Can Help Why Choose Us Customer Reviews FAQs Related Services Contact Us
Overview of Modern APC-Related Therapeutics
Antigen-Presenting Cells (APCs), including dendritic cells and macrophages, are the primary orchestrators of adaptive immunity. Research confirms that the failure of early discovery efforts was often due to poor antigen selection and limited microenvironment infiltration. Creative Biolabs utilizes modern immunological principles, combining strategic neoantigen identification with targeted Antibody-Peptide Conjugates to ensure efficient signaling. By precision-targeting specific cell subsets, we enable the research of immune responses to overcome induced exhaustion.
Request a Consultation →
Fig.1 Summary of endocytic pathways implicated in therapeutic antibodies internalization by DCs. 1
What We Can Offer
One-stop manufacturing service
We provide seamless transition support from initial laboratory-scale discovery through pilot testing and into large-scale research production, ensuring project continuity and specialized technical oversight at every stage.
Stable cell banking services
Long-term integrity of research materials is safeguarded by our internal quality assurance teams, who verify strain origin documentation and confirm cell bank stability. We provide secure storage and regular testing to prevent genetic drift.
Versatile bioprocessing modes
Whether through batch, fed-batch, or continuous processing, our flexible fermentation strategies are designed to maximize the specific yield of unique antibody-peptide payloads. We adapt our bioprocessing parameters to meet the specific metabolic requirements of each lead.
Commitment to sustainable practices
Prioritizing green technologies and biomanufacturing allows your discovery initiatives to align with global ESG standards. We focus on reducing waste and energy consumption while maintaining the highest quality standards for experimental therapeutic production.
How Creative Biolabs Can Assist Your Project
Anti-B7-H4 × CD3 Bispecific Antibody
Anti-B7-H3 × CD3 Bispecific Antibody
By bridging B7-H3 overexpressing tumor cells with CD3+ T-cells, our engineered bispecific antibodies activate potent effector functions to induce targeted lysis while bypassing inhibitory signaling.
Learn More →Anti-4-1BBL Therapeutic Fusion Protein
This initiative focuses on the development of fusion proteins designed for potent 4-1BB co-stimulation. Targeted delivery to specific immune cells enhances T-cell proliferation and fosters long-term antitumor immunity.
Learn More →Anti-CD40 Therapeutic Monoclonal Antibody
Our agonistic antibodies target CD40 to activate antigen-presenting cells, thereby enhancing their T-cell priming capabilities and transforming suppressive microenvironments into immunostimulatory states.
Learn More →Anti-CD70 Therapeutic Fusion Protein
Designed to bolster immune responses against CD70-positive malignancies, these fusion proteins provide co-stimulatory signals through CD27 to drive robust T-cell activation and expansion.
Learn More →Anti-CD70 Therapeutic Monoclonal Antibody
Leveraging high-affinity antibodies, this program blocks the CD70/CD27 pathway or induces antibody-dependent cellular cytotoxicity to effectively inhibit tumor growth and modulate immune signaling.
Learn More →Anti-ICOSL Therapeutic Monoclonal Antibody
We focus on high-affinity antibodies targeting ICOSL to modulate the ICOS pathway, aiming to regulate T-cell activation and memory formation while mitigating adverse research effects.
Learn More →Anti-HHLA2 Therapeutic Monoclonal Antibody
Restoring T-cell and NK-cell activity against HHLA2-expressing tumors is the goal of these specialized antibodies, which block HHLA2/KIR3DL3 or HHLA2/TMIGD2 pathways as a novel checkpoint strategy.
Learn More →Anti-Galectin-9 Therapeutic Monoclonal Antibody
High-affinity antibodies are developed here to block Galectin-9/TIM-3 interactions, effectively reversing T-cell exhaustion and enhancing immunity in refractory or metastatic cancer models.
Learn More →Anti-CD112 Therapeutic Monoclonal Antibody
This program targets CD112 (Nectin-2) to disrupt interactions with inhibitory receptors like TIGIT, thereby enhancing T-cell and NK-cell mediated responses and promoting active immune microenvironments.
Learn More →Anti-CD155 Therapeutic Monoclonal Antibody
To enhance antitumor surveillance, these high-affinity antibodies block CD155/TIGIT immunosuppressive interactions, restoring effector function and inhibiting tumor metastasis and progression.
Learn More →Anti-OX40L Therapeutic Fusion Protein
Critical co-stimulation for T-cell expansion and survival is achieved through engineered fusion proteins that activate the OX40/OX40L pathway to strengthen long-term immunological memory.
Learn More →Anti-GITRL Therapeutic Fusion Protein
These fusion proteins trigger potent co-stimulatory signals via the GITR pathway, enhancing T-cell effector functions and overcoming Treg-mediated suppression for robust antitumor results.
Learn More →Highlights
Integrated Technical Expertise
Creative Biolabs operates at the intersection of molecular design and biological validation. Our expertise allows us to bridge the gap between chemical conjugation and immunology, providing research teams with cohesive developmental support.
Specialized Myeloid Focus
We direct our primary efforts toward the myeloid compartment. By focusing on these specific cell populations, we help researchers orchestrate immune responses more effectively within complex discovery pipelines.
Proven Research Insights
Our extensive background in the field allows us to help projects overcome common obstacles in research models. We provide the necessary insights to navigate the biological barriers that often hinder early-stage discovery.
Precision Delivery Platforms
We utilize proprietary platforms to ensure that research tools reach the intended cellular targets accurately. This focus on precision helps maximize the reliability and performance of your leads.
Reach out to our experts to discuss your specific targets and receive a customized service quote today.
Customer Reviews
-
Superior Linker Stability
The custom pH-sensitive linkers provided for our conjugates ensured zero premature release in systemic circulation. This facilitated a much safer profile and improved metabolic stability during our recent high-resolution pilot study. - Prof. L**a. H. -
AI-Precision
Using Creative Biolabs' AI-selection suite in our research has improved our neoantigen hit rate. We successfully avoided the traditional trial-and-error period, streamlining our entire lead discovery workflow with remarkable computational accuracy. - Dr. J**n. M.
FAQs
How do you ensure the peptide payload isn't degraded before reaching the APC?
We utilize specialized conjugation methods providing steric protection and half-life extension. Stability profiling further verifies conjugate integrity in circulation, ensuring payloads remain intact before reaching targeted intracellular compartments.
Can you target specific DC subsets like cDC1 or pDCs?
Yes. By utilizing antibodies specific to distinct cell markers, we deliver research payloads directly to the subsets most capable of antigen presentation, optimizing the localized immune signaling process.
Related Services
Next-IO™ T Cell-Related Therapeutics
This specialized service focuses on direct T-cell modulation and engineering. We provide validated leads and assays designed to enhance cytotoxic effector functions, reverse exhaustion, and optimize cellular therapy persistence in complex discovery models.
Learn More →Next-IO™ NK Cell-Related Therapeutics
We offer specialized engineering for NK cell activators and engagers. This service provides tools to harness innate cytotoxicity, bypass HLA restriction, and develop potent leads for targeting tumors resistant to traditional T-cell therapies.
Learn More →How to Contact Us
Creative Biolabs' APC-Related Therapeutics represent a shift in how we approach immune modulation research. From AI-optimized antigen selection to complex bispecific and fusion protein programs, we provide the technical depth and biological expertise necessary to turn challenging models into responsive targets.
Our interdisciplinary team of immunologists, chemists, and computational biologists is available to provide technical deep-dives and comprehensive project scoping. We invite you to reach out to our team.
Reference
- Lteif, Maria et al. "Antigen-presenting cell internalization is key for understanding and evaluating therapeutic antibodies' immunogenicity." Frontiers in immunology vol. 16 1617395. 5 Sep. 2025. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2025.1617395
Download our brochureLoading case studies...
Online Inquiry